Archive: 2019

31

Mar2019

Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial

0  
March 31, 2019

07

Mar2019

New Drug Trial Gives Hope for Treatment-Resistant Epilepsy

0  
March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and ... Read More
March 7, 2019

31

Jan2019

A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

0  
January 31, 2019

03

Jan2019

Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication

0  
January, 3 2019, Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced that its drug ABI-009 (sirolimus albumin-bound nanoparticles for injectable suspension) has received Breakthrough Therapy Designation status from the FDA for the indication of Advanced (metastatic or locally advanced) Malignant ... Read More
January 3, 2019